PATENT CLAIM ANALYSIS

Application Number: 16131904
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "315000"]

Abstract:
Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a splice site mutation in intron 4 of the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Claim (Index 13):
The method of  claim 11 , wherein the mutation is G9331A relative to SEQ ID NO: 1.

Metadata:
- Claim Count in Document: 37.0
- Percentile: 97.0
- Lexical Diversity: 1.84
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15459149', '15974217', '13445338', '15338923', '12855468']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7835551274770537
- 35 USC 102 Novelty (BERT): 0.575914630468155
- Combined Prediction Score: 0.7627910777761638
- Mean Citation Score: 394.689524
- Max Citation Score: 536.09155
- Similarity Product: 329.9900892682135

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test